# OnCo record incyte (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/incyte/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "incyte" ;
  schema:name "Incyte"@en ;
  schema:alternateName "Incyte (incl. MorphoSys US rights)"@en ;
  schema:description "Incyte makes pemigatinib, the first targeted drug approved for bile duct cancer (2020), and the JAK inhibitor ruxolitinib."@en ;
  schema:url <https://onco.cc/companies/incyte/>, <https://www.incyte.com> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Incyte> ;
  owl:sameAs <http://www.wikidata.org/entity/Q6015591> ;
  schema:citation <https://www.incyte.com> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/dlbcl/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:drugs <https://onco.cc/drugs/pemigatinib/>, <https://onco.cc/drugs/epacadostat/>, <https://onco.cc/drugs/incb123667/>, <https://onco.cc/drugs/incb161734/>, <https://onco.cc/drugs/inca33890/>, <https://onco.cc/drugs/tafasitamab/> ;
  onco:trials <https://onco.cc/trials/nct03934372/>, <https://onco.cc/trials/nct05287113/>, <https://onco.cc/trials/nct05429268/>, <https://onco.cc/trials/nct04680052/>, <https://onco.cc/trials/nct05222555/>, <https://onco.cc/trials/nct07023627/>, <https://onco.cc/trials/nct02955940/>, <https://onco.cc/trials/nct06465433/>, <https://onco.cc/trials/nct04509700/>, <https://onco.cc/trials/nct05879822/> .